Scholarlink

Background <p>Germline testing for <i>BRCA1</i> and <i>BRCA2</i> has become integral to the management of breast cancer, with pathogenic variants strongly influencing surgical decision-making. However, the increasing detection of variants of uncertain significance (VUS) presents a major clinical challenge, as their implications for cancer risk and treatment remain unclear. This study aimed to evaluate real-world surgical management patterns among breast cancer patients carrying pathogenic <i>BRCA1/2</i> variants or VUS, with a particular focus on determinants of final bilateral mastectomy.</p> Methods <p>This multicenter retrospective study included female breast cancer patients who underwent germline <i>BRCA1/2</i> testing across three institutions in Türkiye between 2017 and 2025. Patients carrying pathogenic variants or VUS were identified and reclassified according to American College of Medical Genetics and Genomics (ACMG) criteria. Clinicopathological characteristics and surgical outcomes were compared between pathogenic and VUS groups. Final bilateral mastectomy was defined as either primary bilateral mastectomy or unilateral mastectomy followed by completion contralateral mastectomy. Multivariable logistic regression was performed to identify factors independently associated with final bilateral mastectomy, including a separate exploratory analysis restricted to VUS carriers.</p> Results <p>A total of 203 patients with abnormal <i>BRCA</i> results were included, comprising 107 pathogenic variant carriers and 96 VUS carriers. Patients with pathogenic <i>BRCA</i> variants were significantly younger at diagnosis and more frequently had triple-negative tumors. Final bilateral mastectomy was markedly more common among pathogenic variant carriers than VUS carriers (67% vs. 12%, <i>p</i> &lt; 0.001). In multivariable analysis, pathogenic <i>BRCA</i> status remained independently associated with final bilateral mastectomy (adjusted OR 10.38, 95% CI 3.98–27.10; <i>p</i> &lt; 0.001), while increasing age was also independently associated.</p> <p>Among VUS carriers, no clinicopathological variable—including molecular subtype, tumor size, Ki-67 index, family history, or <i>BRCA1</i> versus <i>BRCA2</i> VUS—was significantly associated with final bilateral mastectomy in univariate analyses. In exploratory multivariable modeling, younger age at diagnosis emerged as the only independent factor associated with surgical choice (adjusted OR per year 1.09, 95% CI 1.01–1.17; <i>p</i> = 0.027).</p> Conclusion <p>While pathogenic BRCA1/2 variants are strongly associated with bilateral mastectomy in breast cancer patients, surgical decision-making among VUS carriers appears largely independent of tumor biology or genetic subtype and is primarily influenced by age. These findings highlight substantial heterogeneity and potential overtreatment in the management of BRCA VUS carriers, underscoring the need for improved genetic counseling and standardized approaches to mitigate the impact of genetic uncertainty on clinical decision-making.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Breast cancer surgery in the era of genetic uncertainty: real-world outcomes in BRCA1/2 pathogenic variants and variants of uncertain significance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Ilker Nihat Ökten,
  • Tuba Baydaş,
  • Sinan Koca,
  • Mukaddes Feyza Baltacı,
  • Filiz Özen,
  • İbrahim Çil,
  • Metin Eser,
  • Adnan Gündoğdu,
  • Merve Aktaş,
  • Osman Cem Yılmaz

摘要

Background

Germline testing for BRCA1 and BRCA2 has become integral to the management of breast cancer, with pathogenic variants strongly influencing surgical decision-making. However, the increasing detection of variants of uncertain significance (VUS) presents a major clinical challenge, as their implications for cancer risk and treatment remain unclear. This study aimed to evaluate real-world surgical management patterns among breast cancer patients carrying pathogenic BRCA1/2 variants or VUS, with a particular focus on determinants of final bilateral mastectomy.

Methods

This multicenter retrospective study included female breast cancer patients who underwent germline BRCA1/2 testing across three institutions in Türkiye between 2017 and 2025. Patients carrying pathogenic variants or VUS were identified and reclassified according to American College of Medical Genetics and Genomics (ACMG) criteria. Clinicopathological characteristics and surgical outcomes were compared between pathogenic and VUS groups. Final bilateral mastectomy was defined as either primary bilateral mastectomy or unilateral mastectomy followed by completion contralateral mastectomy. Multivariable logistic regression was performed to identify factors independently associated with final bilateral mastectomy, including a separate exploratory analysis restricted to VUS carriers.

Results

A total of 203 patients with abnormal BRCA results were included, comprising 107 pathogenic variant carriers and 96 VUS carriers. Patients with pathogenic BRCA variants were significantly younger at diagnosis and more frequently had triple-negative tumors. Final bilateral mastectomy was markedly more common among pathogenic variant carriers than VUS carriers (67% vs. 12%, p < 0.001). In multivariable analysis, pathogenic BRCA status remained independently associated with final bilateral mastectomy (adjusted OR 10.38, 95% CI 3.98–27.10; p < 0.001), while increasing age was also independently associated.

Among VUS carriers, no clinicopathological variable—including molecular subtype, tumor size, Ki-67 index, family history, or BRCA1 versus BRCA2 VUS—was significantly associated with final bilateral mastectomy in univariate analyses. In exploratory multivariable modeling, younger age at diagnosis emerged as the only independent factor associated with surgical choice (adjusted OR per year 1.09, 95% CI 1.01–1.17; p = 0.027).

Conclusion

While pathogenic BRCA1/2 variants are strongly associated with bilateral mastectomy in breast cancer patients, surgical decision-making among VUS carriers appears largely independent of tumor biology or genetic subtype and is primarily influenced by age. These findings highlight substantial heterogeneity and potential overtreatment in the management of BRCA VUS carriers, underscoring the need for improved genetic counseling and standardized approaches to mitigate the impact of genetic uncertainty on clinical decision-making.